Recent progresses in combination cancer therapy using cyanine dye-based nanoparticles

Pharmaceutical Science Advances, Journal Year: 2024, Volume and Issue: 2, P. 100040 - 100040

Published: March 26, 2024

Surgical resection, radiotherapy, and chemotherapy are traditional methods for cancer treatment. With the development of materials science, photodynamic, photothermal, sonodynamic therapies have been established over past few years. Despite these advances, novel efficient treatment protocols remains highly desirable. Recently, combination therapy has emerged as a powerful tool achieving this goal. In context, cyanine-nanoparticles attracted considerable interest. Cyanine dyes high molar absorptivity, narrow absorption/emission bands, also excellent biocompatibility. This meant that they widely used in biomedical imaging therapy. nanoparticles assembled from cyanine amphiphilic polymers or liposomes endowed with biocompatibility long-term circulation A plethora cyanine–nanoparticle-based systems reported, research discipline continues to expand. review, we aim summarize recent advances cancers using last five years (i.e., 2018 2023), an emphasis on structures dyes, design concepts, strategies. Personal insights challenges field discussed. We expect review will inspire creative progress based facilitate investigation future clinical applications.

Language: Английский

---

[Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy 
in Elderly Patients with Advanced NSCLC].

PubMed, Journal Year: 2024, Volume and Issue: 27(5), P. 367 - 375

Published: May 20, 2024

The incidence of cancer is closely correlated with age, as 75% non-small cell lung (NSCLC) patients are aged at least 65 years. availability immune checkpoint inhibitors (ICIs) has altered the available NSCLC therapeutic pattern. Limited studies on elderly have demonstrated that ICIs monotherapy provide substantial benefits for 65-75 years, showing no significant difference compared to younger patients. This benefit also observed in combination immune-combined chemotherapy or radiotherapy. For individuals older than 75 survival effect was not evident, though. Immune-related adverse events (irAEs) alone were similar across age categories. Immune-combination resulted a higher irAEs alone, and ≥75 years more likely experience higher-grade irAEs. Besides fact immunosenescence influences milieu multifaceted manner, which turn impacts effectiveness immunotherapy, prognosis influenced by Eastern Cooperative Oncology Group performance status (ECOG PS) score, among other factors. certain poor physical health, immunotherapy combined low-intensity emerged viable treatment option. However, there fewer related studies, so should be conscious effort increase number enrolled trial comprehensive assessment explore individualized options. To additional references guidance propose new perspectives their characteristics, this review aims summarize analyze pertinent application programmed death protein 1 (PD-1)/programmed ligand (PD-L1) these .

Language: Английский

---

Research progress on platelets in glioma

Chinese Medical Journal, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 10, 2024

Abstract Gliomas are the most common primary neuroepithelial tumors of central nervous system in adults, which glioblastoma is deadliest subtype. Apart from intrinsically indestructible characteristics glioma (stem) cells, accumulating evidence suggests that tumor microenvironment also plays a vital role refractoriness glioblastoma. The functions platelets to stop bleeding and regulate thrombosis under physiological conditions. Furthermore, active elements participate variety processes development, including growth, invasion, chemoresistance. Glioma cells recruit activate resting become tumor-educated (TEPs), turn can promote proliferation, stemness, chemoresistance cells. TEPs be used obtain genetic information about gliomas, helpful for early diagnosis monitoring therapeutic effects. Platelet membranes intriguing biomimetic materials developing efficacious drug carriers enhance antiglioma activity. Herein, we review recent research referring contribution malignant gliomas focusing on molecular mechanisms mediating interaction between as well present challenges opportunities targeting therapy.

Language: Английский

---

Progress of Immunotherapy Combined with Anti-Angiogenesis Therapy in Lung Cancer

Journal of Biosciences and Medicines, Journal Year: 2024, Volume and Issue: 12(09), P. 183 - 195

Published: Jan. 1, 2024

Language: Английский

---

Contemporary strategies in glioblastoma therapy: Recent developments and innovations

Neuroscience, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

---